Kazuki Yamada, Satoshi Suzuki, Y. Tanino, Keiko Suzuki, T. Ichikawa, Masahide Nakajima, A. Tampo, S. Kukita, Shohei Kuroda, A. Uehara, Hidemitsu Sakagami, Yuuki Nagashima, A. Nakamura, Kae Takahashi, Seisuke Saito, Roku Sato, Y. Kakinoki
{"title":"抗体鸡尾酒疗法治疗COVID-19的临床研究","authors":"Kazuki Yamada, Satoshi Suzuki, Y. Tanino, Keiko Suzuki, T. Ichikawa, Masahide Nakajima, A. Tampo, S. Kukita, Shohei Kuroda, A. Uehara, Hidemitsu Sakagami, Yuuki Nagashima, A. Nakamura, Kae Takahashi, Seisuke Saito, Roku Sato, Y. Kakinoki","doi":"10.11150/kansenshogakuzasshi.96.179","DOIUrl":null,"url":null,"abstract":"Background: Randomized phase III clinical trials suggest that the antibody cocktail containing casirivimab and imdevimab reduces the risk of hospitalization/death in high-risk COVID-19 patients. However, the efficacy of the cocktail in daily clinical practice remains unknown.","PeriodicalId":17713,"journal":{"name":"Kansenshogaku Zasshi","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Study of Antibody Cocktail Therapy for COVID-19\",\"authors\":\"Kazuki Yamada, Satoshi Suzuki, Y. Tanino, Keiko Suzuki, T. Ichikawa, Masahide Nakajima, A. Tampo, S. Kukita, Shohei Kuroda, A. Uehara, Hidemitsu Sakagami, Yuuki Nagashima, A. Nakamura, Kae Takahashi, Seisuke Saito, Roku Sato, Y. Kakinoki\",\"doi\":\"10.11150/kansenshogakuzasshi.96.179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Randomized phase III clinical trials suggest that the antibody cocktail containing casirivimab and imdevimab reduces the risk of hospitalization/death in high-risk COVID-19 patients. However, the efficacy of the cocktail in daily clinical practice remains unknown.\",\"PeriodicalId\":17713,\"journal\":{\"name\":\"Kansenshogaku Zasshi\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kansenshogaku Zasshi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11150/kansenshogakuzasshi.96.179\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kansenshogaku Zasshi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11150/kansenshogakuzasshi.96.179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical Study of Antibody Cocktail Therapy for COVID-19
Background: Randomized phase III clinical trials suggest that the antibody cocktail containing casirivimab and imdevimab reduces the risk of hospitalization/death in high-risk COVID-19 patients. However, the efficacy of the cocktail in daily clinical practice remains unknown.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
